Targovax ASA: PDMR notices

Oslo, 27 October 2021: Reference is made to the mandatory notifications of trade by primary insiders sent by Targovax ASA ("Targovax" or the "Company") on 21 October 2021, 3 October 2021, 2 July 2021 and 18 March 2021.

Please see the attached notifications of trading pertaining to the abovementioned mandatory notifications of trade by primary insiders.

21.10.2021 Notification by Primary Insiders_Wiklund.pdf

03.10.2021 Notification by Primary Insiders_Melin.pdf

02.07.2021 Notification by Primary Insiders_Ottesen.pdf

18.03.2021 Notifications by Primary Insiders_Board.pdf

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 906 56 525
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying its multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The company’s product candidates are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging clinical data in several indications, both in monotherapy and in multiple combinations, the next development steps for ONCOS-102 will be to further improve responses in melanoma patients resistant to or poorly responsive to current standard of care.